TABLE 5.
GRADE evidence profile1
| Outcome | Studies n | Study design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | ES (95% CI) | Assumed risk | Absolute risk (95% CI) | Certainty |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total potato | |||||||||||
| Total cancer | 18 | Cohort | Serious | Not serious | Not serious | Serious | None | 1.04 (0.96, 1.11) | 68 per 10000 | 2.72 per 10000(–7.48 to 2.75) | ⊕⊕◯◯Lowdue to risk of bias and imprecision |
| CRC | 9 | Cohort & case-control | Serious | Not serious | Not serious | Serious | None | 1.11 (0.97, 1.28) | 81 per 10000 | 8.9 per 10000(–22.68 to 2.43) | ⊕⊕◯◯Lowdue to risk of bias and imprecision |
| Colon cancer | 4 | Cohort & case-control | Serious | Not serious | Not serious | Serious | None | 1.09 (0.93, 1.28) | 68 per 10000 | 6.12 per 10000(–19.04 to 4.27) | ⊕⊕◯◯Lowdue to risk of bias and imprecision |
| Rectal cancer | 2 | Cohort | Serious | Not serious | Not serious | Serious | None | 1.47 (1.10, 1.98) | 17 per 10000 | 7.99 per 10000(–16.66 to –1.7) | ⊕⊕◯◯Lowdue to risk of bias and imprecision |
| Pancreatic cancer | 5 | Cohort & case-control | Serious | Not serious | Not serious | Serious | None | 1.21 (1.01, 1.45) | 19 per 10000 | 3.99 per 10000(–8.55 to –0.19) | ⊕⊕◯◯Lowdue to risk of bias and imprecision |
| Gastric cancer | 7 | Case-control | Serious | Serious | Not serious | Serious | None | 1.005 (0.69, 1.46) | 137 per 10000 | 0.68 per 10000(–63.02 to 42.47) | ⊕◯◯◯Very lowdue to risk of bias, imprecision, and inconsistency |
| Breast cancer | 4 | Cohort & case-control | Serious | Not serious | Not serious | Serious | None | 0.98 (0.85, 1.12) | 130 per 10000 | 2.6 per 10000(–15.6 to 19.5) | ⊕⊕◯◯Lowdue to risk of bias and imprecision |
| Prostate cancer | 5 | Cohort & case-control | Serious | Not serious | Not serious | Serious | None | 1.03 (0.95, 1.10) | 204 per 10000 | 6.12 per 10000(–20.4 to 10.2) | ⊕⊕◯◯Lowdue to risk of bias and imprecision |
| Renal cancer | 2 | Cohort & case-control | Serious | Not serious | Not serious | Serious | None | 0.73 (0.48, 1.06) | 24 per 10000 | 6.48 per 10000(–1.44 to 12.48) | ⊕⊕◯◯Lowdue to risk of bias and imprecision |
| Lung cancer | 2 | Cohort & case-control | Serious | Not serious | Not serious | Serious | None | 0.80 (0.49, 1.29) | 4781 per 10000 | 956 per 10000(–1386 to 2438) | ⊕⊕◯◯Lowdue to risk of bias and imprecision |
| Bladder cancer | 5 | Case-control | Serious | Serious | Not serious | Serious | None | 0.72 (0.46, 1.14) | 5094 per 10000 | 956 per 10000(–713 to 1426) | ⊕◯◯◯Very lowdue to risk of bias, imprecision, and inconsistency |
| Fried potato | |||||||||||
| Gastrointestinal cancers | 9 | Cohort & case-control | Serious | Not serious | Not serious | Serious | None | 1.03 (0.89, 1.19) | 81 per 10000 | 2.43 per 10000(–15.39 to 8.91) | ⊕⊕◯◯Lowdue to risk of bias and imprecision |
| Sex-hormone-related cancers | 6 | Cohort & case-control | Serious | Not serious | Not serious | Serious | None | 1.01 (0.91, 1.11) | 130 per 10000 | 1.3 per 10000(–14.3 to 11.7) | ⊕⊕◯◯Lowdue to risk of bias and imprecision |
| Urinary-related cancers | 9 | Cohort & case-control | Serious | Serious | Not serious | Serious | None | 1.26 (0.82, 1.93) | 3283 per 10000 | 853 per 10000(–3053 to 590) | ⊕◯◯◯Very lowdue to risk of bias, imprecision, and inconsistency |
| Lung cancer | 2 | Cohort & case-control | Serious | Serious | Not serious | Serious | None | 1.26 (0.86, 1.95) | 57 per 10000 | 14.82 per 10000(–54.15 to 7.98) | ⊕◯◯◯Very lowdue to risk of bias, imprecision, and inconsistency |
1
Symbols indicate the following strength of evidence: ⊕⊕⊕⊕, high (further research is very unlikely to change our confidence in the estimate of association); ⊕⊕⊕◯, moderate (further research is likely to have an important impact on our confidence in the estimate of association and may change the estimate); ⊕⊕◯◯, low (further research is very likely to have an important impact on our confidence in the estimate of association and is likely to change the estimate); and ⊕◯◯◯, very low (any estimate of association is very uncertain). CRC, colorectal cancer; ES, effect size; GRADE, Grading of Recommendations, Assessment, Development and Evaluation.